论文部分内容阅读
目的比较万古霉素与利奈唑胺治疗耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染的疗效及安全性。方法选取2012年5月-2013年5月109例MRSA肺部感染患者为研究对象,将其分为万古霉素组73例及利奈唑胺组36例,万古霉素组予以万古霉素1.0g,每12h1次进行治疗,利奈唑胺组予以利奈唑胺0.6g,每12h1次进行治疗,观察两组患者治疗后的临床效果及安全性。结果治疗总有效率万古霉素组为76.71%、利奈唑胺组为61.11%,两组比较差异有统计学意义(P<0.05);而两组患者治疗后白细胞计数、C-反应蛋白、中性粒细胞比值、降钙素原及并发症发生率比较差异无统计学意义。结论对MRSA肺部感染患者,万古霉素与利奈唑胺敏感性均较高,总体疗效万古霉素略高,且安全性和耐受性较利奈唑胺略高。
Objective To compare the efficacy and safety of vancomycin and linezolid in the treatment of pulmonary infection with methicillin-resistant Staphylococcus aureus (MRSA). Methods From May 2012 to May 2013, 109 patients with MRSA pulmonary infection were selected and divided into three groups: vancomycin group (n = 73) and linezolid group (n = 36). Vancomycin group received vancomycin 1.0g , Treated every 12h1 times. The linezolid was treated with linezolid 0.6g every 12h and the clinical effects and safety of the two groups were observed. Results The total effective rate of treatment was 76.71% in vancomycin group and 61.11% in linezolid group, with significant difference between the two groups (P <0.05). The white blood cell count, C-reactive protein, The ratio of granulocyte, procalcitonin and the incidence of complications was no significant difference. Conclusion For patients with MRSA pulmonary infection, vancomycin and linezolid are more sensitive and the overall effect is slightly higher than that of vancomycin, and the safety and tolerability are slightly higher than that of linezolid.